Increasing Sensitivity and Minimizing Sample Volume for the Quantification of Therapeutic and Endogenous Cyclic Peptides in Plasma Using ionKey/MS

Mary E. Lame, Erin E. Chambers, and Kenneth J. Fountain Waters Corporation, Milford, MA, USA

APPLICATION BENEFITS

- High sensitivity assay with LOQ of <1 pg/mL with only 100 µL of plasma
- Use of the ionKey/MS[™] System facilitates detection limits of 2.5 pg/mL from only 25 µL of plasma
- Use of mixed-mode solid-phase extraction (SPE) reduces matrix interferences and enhances selectivity of the extraction in plasma
- 96-well µElution plate format enables concentration of the sample while maintaining solubility and minimizes peptide loss due to adsorption
- Selective, fast SPE extraction (<30 minutes) without time-consuming immuno-affinity purification
- Reduced solvent consumption (40X) compared to 2.1 mm scale means significant cost savings

WATERS SOLUTIONS

ionKey/MS System <u>ACQUITY UPLC® M-Class System</u> ionKey[™] Source Xevo® TQ-S Mass Spectrometer iKey[™] Separation Device Oasis® WCX 96-well µElution Plate Waters Collection Plate MassLynx® <u>4.1 Software</u> TargetLynx[™] Software

KEY WORDS

bioanalysis, Oasis, sample preparation, peptide quantification, octreotide, desmopressin, vasopressin, UPLC, 2D Technology, plasma, ionKey/MS, iKey, ionKey/MS

INTRODUCTION

The use of peptides and proteins as therapeutic agents has increased significantly in recent years. Thus, the demand for their analysis for toxicokinetic and pharmacokinetic studies is increasing as well.

Historically, biologics have been quantified using ligand binding assays (LBAs). However, with recent advances in mass spectrometry (MS) and liquid chromatography (LC) technologies current approaches towards peptide quantification in biological fluids now include LC-MS/MS. This is in part driven by the fact that LBAs can suffer from significant cross-reactivity issues and lack of standardization. Additionally, LC-MS/MS also has the advantage of greater accuracy and precision, broader dynamic ranges, specificity, and speed of method development. However, accurate guantification of peptides by LC-MS/MS is often not without its own challenges. Peptides have diverse pharmacokinetic profiles, often low circulating plasma levels (pg/mL), generally low MS sensitivity, and require chromatographic resolution from endogenous isobaric matrix interferences.¹ Therefore, to achieve low pg/mL quantification limits, large plasma sample volumes (0.2–1 mL) and sample injection volumes are often required.²⁻⁶ These volumes are often impractical in discovery studies. Thus, the demand for quantitative bioanalytical assays that use decreased sample volumes, while maintaining or improving sensitivity are highly desired.

This application investigates the improved sensitivity and decreased sample volume requirements for the therapeutic and endogenous cyclic peptides: desmopressin, vasopressin and octreotide.⁷⁻⁹ The general properties of these peptides are shown in Table 1. Using a combination of selective μ Elution mixed-mode SPE sample preparation, optimal MS precursor and fragment choice, and the ionKey/MS System (source shown in Figure 1), limits of quantification of 1 pg/mL in plasma were achieved. Capitalizing on the attributes of the ionKey/MS System facilitated reducing plasma sample required to 25–100 μ L.

EXPERIMENTAL

Method conditions

UPLC conditions					
LC system:	ACQUITY UPLC M-Class, configured for trap and back-flush elution				
Separation device:	iKey HSS T3, 1.8 μm, 100Å, 150 μm x 100 mm iKey (<u>p/n 186007261)</u>				
Trap column:	ACQUITY UPLC M-Class Symmetry [®] C ₁₈ , 5 μm, 300 μm x 50 mm (<u>p/n 186007498</u>)				
Mobile phase A:	0.1% formic acid in water				
Mobile phase B:	0.1% formic acid in acetonitrile				
Loading solvent:	98:2 mobile phase A:B, 25 μL/min for first two minutes, reverse valve				
Valve position:	Initial position one (forward loading of trap), switch to position two at two minutes (back flush elute of trap onto the analytical column)				
Analytical gradient:	See Table 2				
Elution flow rate:	3.0 μL/min				
iKey temp.:	75 °C				
Sample temp.:	15 °C				
Injection volume:	5 μL				
Total run time:	12.0 min				
Collection plates:	Waters 1 mL Collection Plates				

MS conditions

MS system:	Xevo TQ-S
lonization mode:	ESI positive
Capillary voltage:	3.8 kV
Source temp.:	120 °C
Cone gas flow:	100 L/hr
Collision cell pressure:	5.5 x 10 ⁽⁻³⁾ mbar
Collision energy	Optimized by component, see Table 3
Cone voltage:	Optimized by component, see Table 3

Data management

Chromatography	
software:	MassLynx 4.1
Quantification	
software:	TargetLynx

2

Table 1. Peptide chemical properties.

Peptide	Amino acid sequence	MW	pl	HPLC index
Octreotide	8Phe-Cys-Phe-Trp-Lys-Thr-Cys-Thr-ol [Disulfide bridge: 2-7]	1019	9.3	40.8
Desmopressin	Mpa-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 [Disulfide Bridge: 1-6]	1069	8.6	16.8
Vasopressin	Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 [Disulfide Bridge: 1-6]	1084	9.1	7.6



Gradient:	Time (min)	Profile %A %B		Curve
	0.0	98	2	6
	5.0	50	50	6
	5.5	50	50	6
	7.0	10	90	6
	8.0	10	90	6
	9.0	98	2	6

Figure 1. ionKey Source.

Table 2. LC gradient conditions.

Sample preparation

Sample pre-treatment

100 μ L of human plasma was diluted 1:1 with 4% H₃PO₄ in water and mixed.

Sample extraction with Oasis WCX

Pre-treated plasma samples were extracted according to the protocol in Figure 2. All solutions are made up by volume. All extraction steps were applied to all wells of the µElution plate that contained samples.

Oasis WCX µElution Protocol	
Part number: <u>186002499</u>	
Condition: 200 µL MeOH	
Equilibrate: 200 μL H ₂ O	
Load: 200 µL Diluted Plasma	
Wash 1: 200 μL 5% NH₄OH in H₂O	
Wash 2: 200 μL 10% ACN in H ₂ O	
Elute: 2 x 25 μL of 2% FA in 50:50 ACN:H ₂ O	
Dilute: 50 μL H ₂ O	Figure 2. Oasis µElution WCX extraction protocol.

Increasing Sensitivity a	and Minimizing Sample	Volume for the Quantification of	Therapeutic and Endogenous	Cuclic Peptides

3

RESULTS AND DISCUSSION

Mass spectrometry

The 2+ precursors of desmopressin (m/z 535.45), vasopressin (m/z 542.75), and octreotide (m/z 510.30) were used for quantitation. Their corresponding fragments and optimal MS conditions are shown in Table 3. In this assay, the use of highly specific b/y ion specific fragments was more challenging due to the small size and cyclic nature of these peptides. The fragment at m/z328.2, corresponding to a y3¹⁺ ion, was chosen for desmopressin and vasopressin. The fragment at m/z 120.1, corresponding to the phenylalanine immonium ion, was used for octreotide. Table 3. MS conditions for cyclic peptides.

Peptide	Precursor	MRM Precursor Transition		Collision Energy (eV)	Product Ion type
Desmopressin	[M+2H] ²⁺	535.4>328.2	40	12	y3 ⁽¹⁺⁾
Vasopressin	[M+2H] ²⁺	542.7>328.2	40	14	y3 ⁽¹⁺⁾
Octreotide	[M+2H] ²⁺	510.3>120.1	25	17	immonium ion (Phe)

Chromatographic separation

Chromatographic separation was achieved using the novel microfluidic chromatographic iKey Separation Device. The iKey Separation Device (Figure 3) is packed with UPLC[®]-grade sub-2-µm particles that permit operation at high pressure and results in highly efficient LC separations. By integrating microscale LC components into a single platform design, problems associated with capillary connections, including manual variability, leaks, and excessive dead volume, are avoided. Use of the iKey HSS T3, 1.8 µm, 100Å, 150 µm x 100 mm (p/n 186007261) provided chromatographic retention, excellent peak shape, narrow peak widths (<4.5 seconds at base), and resolution from endogenous matrix interferences.



Figure 3. iKey Separations Device.

The peptides were eluted using a linear gradient from 2–50% B over 5 minutes, Table 2. Representative chromatograms are shown in Figure 4. The use of a trap and back-flush elution strategy, provided further sample cleanup and facilitated the loading of 5 μ L of the high organic SPE eluate (required to maintain solubility of the peptides) without experiencing analyte breakthrough. Additionally, the ability to inject sample volumes typical for 2.1 mm analytical scale LC analysis on the iKey Separation Device can provide the substantial gains in sensitivity that are often required to accurately and reliably detect low pg/mL levels of peptides and proteins in complex matrices.




Figure 4. UPLC separation of desmopressin, vasopressin, and octreotide, using the iKey HSS T3, 1.8 μm, 100Å, 150 μm x 100 mm (<u>p/n 186007261)</u>.

Enhanced sensitivity with the use of ionKey/MS

Versus analytical scale (2.1 mm I.D.), the ionKey/MS System generally offers increased sensitivity, making it ideal for high sensitivity peptide analysis. This also facilitates the use of smaller sample volumes whilst maintaining or improving sensitivity. In Figures 5 and 6, detection of 2.5 pg/mL of desmopressin and octreotide was easily obtained from extraction of 25, 100, or 200 µL human plasma, using injection volumes ≤10 µL.




Figure 5. Enhanced sensitivity using the ionKey/MS System: Extraction volume comparison of desmopressin (2.5 pg/mL) from human plasma.




Figure 6. Enhanced sensitivity using the ionKey/MS System: Extraction volume comparison of octreotide (2.5 pg/mL) from human plasma.

Sample preparation

SPE was performed using Oasis WCX, which has both reversed-phase and ion-exchange modes of retention. The orthogonality introduced by the use of mixed-mode sorbents such as these enables greater sample cleanup, improved selectivity, and the sensitivity required for these peptides. Briefly, desmopressin, vasopressin, and octreotide were spiked at various concentrations into the plasma and mixed. These samples were then acidified with 4% H₃PO₄, which helped disrupt protein binding and reduce sample viscosity, improving contact time with the sorbent. Samples were loaded to the SPE device, and washed with 5% NH₄OH followed by 10% acetonitrile. The optimum elution solution was 50% organic, 25% water, with 2% formic acid.

The 96-well Oasis µElution Plate format facilitates fast sample processing (under 30 minutes), and is compatible with automation by most liquid-handling robotic systems, improving sample throughput. Additionally, this format also provides the ability to elute in very small sample volumes, minimizes the potential for adsorptive peptide losses, as well as concentrates the sample for increased sensitivity.

Linearity, accuracy, and precision

To generate standard curves, human plasma was fortified with desmopressin, vasopressin and octreotide at the following final concentrations: 1, 2.5, 5, 10, 25, 50, 100, 250, 500, 1000, and 2000 pg/mL. SPE of the fortified plasma samples was performed as described above. The calibration curves were constructed using peak areas of the calibration samples by applying a one/concentration (1/x) weighted linear regression model. Using 100 µL of plasma, calibration lines were obtained for each peptide and are shown in Figure 7, panels A, B, C.








Figure 7. Calibration lines obtained for the quantification of desmopressin (A), vasopressin (B), and octreotide (C) in extracted plasma.


A summary of standard curve performance is shown in is shown in Table 4. Using 1/X regressions, quantification was linear from 1–2,000 pg/mL with R² values of >0.99 for all 3 peptides monitored. Representative chromatograms for extracted desmopressin, vasopressin, and octreotide plasma standard samples are shown in Figures 8–10.














8

Table 4.	Summary	of	^r standard	curve	performance.
----------	---------	----	-----------------------	-------	--------------

Desmopressin plasma concentration (pg/mL)	Area	Calculated desmopressin concentration (pg/mL)	Mean accuracy	Vasopressin plasma concentration (pg/mL)	Area	Calculated vasopressin concentration (pg/mL)	Mean accuracy	Octreotide plasma concentration (pg/mL)	Area	Calculated octreotide concentration (pg/mL)	Mean accuracy
1.0	215	0.95	94.8	1.0	107	0.98	98.9	1.0	668	1.06	106.0
2.5	319	2.58	103.5	2.5	193	2.50	99.9	2.5	1474	2.38	95.3
5.0	453	4.70	94.3	5.0	344	5.15	103.1	5.0	3017	4.91	98.1
10.0	898	11.75	117.5	10.0	646	10.50	104.8	10.0	5820	9.50	95.0
25.0	1965	28.63	114.5	25.0	1551	26.38	105.6	25.0	16404	26.82	107.3
50.0	3363	50.70	101.5	50.0	2781	48.05	96.1	50.0	29385	48.08	96.2
100.0	6376	98.35	98.4	100.0	5454	95.08	95.1	100.0	59131	96.77	96.8
250.0	15625	244.60	97.9	250.0	13751	241.10	96.5	250.0	149267	244.34	97.8
500.0	33594	528.68	105.7	500.0	28805	506.05	101.2	500.0	304504	498.48	99.7
1000.0	62242	981.60	98.2	1000.0	55252	971.53	97.2	1000.0	584899	957.52	95.8
2000.0	126145	1991.95	99.6	2000.0	115450	2030.98	101.5	2000.0	1251918	2049.51	99.7

CONCLUSIONS

The combination of the ionKey/MS System and mixed-mode µElution SPE provided enhanced selectivity and increased sensitivity, whilst simultaneously significantly reducing sample volume requirements. Use of µElution format SPE eliminated the need for evaporation, reducing peptide losses due to adsorption and non-specific binding. The 150 µm iKey Separation Device enabled the development of a highly sensitive, low flow guantitative MRM method that simultaneously detects vasopressin, desmopressin, and octreotide with LOD lpg/mL, and dynamic ranges from 1–2,000 pg/mL. The current analysis uses 100 µL of plasma and provides a significant improvement in sensitivity and S:N over analytical scale (2.1 mm I.D.) analysis. Furthermore, detection limits of 2.5 pg/mL are achievable from only 25 μ L of plasma. In addition, the ionKey/MS System reduces solvent and sample consumption, thereby reducing cost and allowing for multiple injections of samples for improved accuracy or to meet the guidelines for incurred sample reanalysis (ISR).

References

- 1. Ewles M, Goodwin L, Bioanalytical approaches to analyzing peptides and proteins by LC-MS/MS. *Bioanalysis* (2011) 3(12), 1379-1397.
- 2. Jiang Y, Wang J, Wang Y, Du X, Zhang Y, Fawcett JP, Gu J, Determination of long-acting release octreotide, an octapeptide analogue of somatostation, in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2007; 21: 3982–3986.
- 3. Sidibé J, Varesio E, Hopfgartner G, Quantification of ghrelin and des-acyl ghrelin in human plasma by using cubicselected reaction-monitoring LCMS. *Bioanalysis* May 2014, Vol. 6, No. 10, Pages 1373–1383.
- 4. Kim MK, Lee TH, Suh JH, Eom HY, Min JW, Yeom H, Kim U, Jung HJ, Cha KH, Choi YS, Youm JR, Han SB, Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of goserelin in rabbit plasma. Journal of Chromatography B, 878 (2010) 2235-2242.
- 5. Neudert, L, Zaugg M, Wood S, Struwe P, High Sensitivity Dual Solid Phase Extraction LC-MS/MS Assay for the Determination of the Therapeutic Peptide Desmopressin in Human Plasma. Celerion eHistory, accessed July 6, 2014, http://celerion.com/wordpress/wp-content/uploads/ 2011/09/A-High-Sensitivity-Dual-Solid-Phase-Extract-LC-MSMS-Assay-for-the-Determination-of-the-Therapeutic-Peptide-Desmopressin-in-Human-Plasma_2011.pdf
- 6. Morin LP, Landry F, Mess JN, Jonakin K, Aiello M, Misonne X, Gary Impey, Cardenas J and Garofolo F, Challenge in Trying to Reach Femtogram per Milliliter (fg/mL) Sensitivity in Plasma for the Quantification of a Cyclic Peptide: Desmopressin. Poster session presented at: 61st Annual Conference of the American Society for Mass Spectrometry; 2013 June 9–13; Minneapolis, MN.
- 7. JHP (2010) Vasopressin Injection United States drug package insert http://www.parsterileproducts.com/ products/PI/00011052013/JHP-Pharmaceuticals-Pitressin-00011052013.pdf
- 8. Ferring (2008) Desmopressin United States drug package insert. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/PediatricAdvisoryCommittee/ UCM215090.pdf
- 9. Novartis (1988) Octreotide United States drug package insert http://www.pharma.us.novartis.com/cs/www.pharma. us.novartis.com/product/pi/pdf/sandostatin_lar.pdf

Vaters

THE SCIENCE OF WHAT'S POSSIBLE.

Waters, The Science of What's Possible, ACQUITY UPLC, Xevo, Oasis, MassLynx, Symmetry, and UPLC are registered trademarks of Waters Corporation. ionKey/MS, ionKey, iKey, and TargetLynx are trademarks of Waters Corporation. All other trademarks are the property of their respective owners.

©2014–2016 Waters Corporation. Produced in the U.S.A. January 2016 720005128EN AG-PDF

Waters Corporation 34 Maple Street Milford, MA 01757 U.S.A. T: 1 508 478 2000 F: 1 508 872 1990 www.waters.com